SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN) in connection with the proposed acquisition of the Company by AstraZeneca PLC ("AstraZeneca"), a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines.  Under the terms of the acquisition agreement, the Company's shareholders will receive $60.00 per share in cash and 2.1243 AstraZeneca American Depositary Shares ("ADSs") (each ADS representing one-half of one ordinary share of AstraZeneca, as evidenced by American Depositary Receipts ("ADRs")) for each share of Alexion common stock that they hold.  Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $175 per share.

If you own Alexion shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

http://www.weisslawllp.com/ALXN/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

WeissLaw is investigating whether (i) Alexion's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates Alexion's shareholders; and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, at least one analyst has set a price target for the Company of $200.00, and the merger consideration is 14% below the Company's all time high stock price.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc-301192370.html

SOURCE WeissLaw LLP